Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
Conference activity picks up, with the big one – ASCO – at the end of the month.
Three off-the-shelf mRNA therapies join intismeran autogene.
New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
Antibody-drug conjugates hitting this target abound.
